EuroBiotech—More articles of note

Newspapers
(NS Newsflash/CC BY 2.0)

> E-Therapeutics (ETX) struck agreements with Intellegens and Biorelate to access artificial intelligence tools. Pilot studies suggest the tools complement ETX’s computational drug discovery technology. Statement

> ValiRx presented an analysis of data from a phase 2 trial of cancer candidate VAL401. Release 

> Avacta and Glythera entered into a licensing agreement. The signing of the deal follows an initial study to evaluate the use of Avacta's Affimer technology with Glythera's conjugation chemistry. Statement

> British trade group The BioIndustry Association secured clearance to intervene in a Supreme Court patent case. The BIA is concerned the court’s ruling could affect how much data and evidence companies need to patent inventions. Release

> Transgene’s China joint venture dosed the first hepatitis B patient in a phase 1 trial. Statement

> TxCell snagged a government loan to support preclinical development of its lead CAR-Treg program. Release

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.